Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1. - Wikidata - awgldk - TriplyDB

Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1.

Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1.

http://www.wikidata.org/entity/Q36865546

about

Development of a Pediatric Physiologically Based Pharmacokinetic Model for Sirolimus: Applying Principles of Growth and Maturation in Neonates and Infants.Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia.Characterizing the Developmental Trajectory of Sirolimus Clearance in Neonates and Infants Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children.Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group.Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infants with complicated vascular anomalies.Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study.

P2860

Q35179536-82E8251E-CAF2-414E-9B4E-5A0C7773CA2E Q35788825-52E0A32A-4B16-4C5E-ABF7-E4F5B1FC180F Q36706798-73C8528E-A64D-4AB9-A3EC-A36BD23402B0 Q37208505-08C1BE42-5EBF-4D86-A157-176FD05A2B45 Q38527434-7BAF53C2-8EE1-430F-BE8A-40547A6ECA0A Q38779903-BFD6EE7B-7FE8-42BA-8434-7C51722D8F1E Q38958282-5229E518-DA81-41BF-B1F4-250CF4463680 Q47872951-F7D5D24A-2019-4043-862A-3CBD461A2318

P2860

Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1.

http://www.wikidata.org/entity/Q36865546

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Population pharmacokinetics of ...... with neurofibromatosis type 1.

@en

type

label

Population pharmacokinetics of ...... with neurofibromatosis type 1.

@en

prefLabel

Population pharmacokinetics of ...... with neurofibromatosis type 1.

@en

P1433

Q36865546-11AFEE37-C7B2-406F-85FF-2EE3CF2D87E5

P1476

Q36865546-0912E814-2DCC-424A-8022-3A08314F2095

P2093

Q36865546-1FB8ECE2-CC8D-4298-A18A-8508BD1F9BE5

Q36865546-5F8C1C5A-0B01-4668-9301-B69F9FABE96B

Q36865546-685F1DD8-B19C-4A75-BF98-7FCCFE608340

Q36865546-6A90565C-D5B3-4A89-8EB9-6E3EF90C5CED

Q36865546-96CE5F05-FF00-4C94-A86B-0B5DE33DCB4B

Q36865546-AFF8297C-0FC9-4021-A425-FD73B938147A

Q36865546-CD40E92B-0D8E-4045-AF1C-1204114B95E1

Q36865546-EDAD8659-F2C2-4B5C-843A-25EDF5C2BDBE

P2860

Q36865546-0598D713-AB2D-41BB-AD68-016F93B26E5F

Q36865546-05A59E3F-0248-483C-B643-3EE3B4778B20

Q36865546-0AEEAD26-10F8-406F-BB39-0A2B94A512E3

Q36865546-0E12F5C1-FBB2-4600-8601-D48C3F757AC3

Q36865546-0FB3E26E-D3BD-4F7F-81BE-88039F936614

Q36865546-11F616E8-4836-4AC5-9ED6-836CDE62F6DB

Q36865546-1B6410A6-087B-48A5-8A1C-0479B18A7BAB

Q36865546-296037F8-7873-48DA-81C6-D350F67F653B

Q36865546-2A03E42F-FF23-4D2F-8676-71DF27EDC149

Q36865546-2D026872-B04E-43A0-98AC-C5CE3C31DD2B

P304

Q36865546-0B0599CF-4355-48D0-94CC-6A519F7A04ED

P31

Q36865546-3E9DA309-A993-4A82-A3F7-9732254216B5

P356

Q36865546-F690BF0B-A1CA-4E81-9958-B867BCEF5FDE

P433

Q36865546-9C536447-8397-49A3-8EF8-9C62D2DE73F9

P478

Q36865546-410126A8-0A30-4F14-9753-1C2596241908

P577

Q36865546-6F398DA1-453B-4EF5-B22D-00C923809F05

P698

Q36865546-B18D5EC0-01D7-45D7-A6A6-0B5BA6625CB1

P932

Q36865546-B91E100D-4A08-47CC-A108-98E8CB87629F

P356

FTD.0B013E318286DD3F

P1433

Therapeutic Drug Monitoring

P1476

Population pharmacokinetics of ...... with neurofibromatosis type 1.

@en

P2093

Alexander A Vinks

http://www.w3.org/2001/XMLSchema#string

Brian Weiss

http://www.w3.org/2001/XMLSchema#string

Brigitte C Widemann

http://www.w3.org/2001/XMLSchema#string

Jeffrey R Scott

http://www.w3.org/2001/XMLSchema#string

John Perentesis

http://www.w3.org/2001/XMLSchema#string

Joshua D Courter

http://www.w3.org/2001/XMLSchema#string

Michael Fisher

http://www.w3.org/2001/XMLSchema#string

Shannon N Saldaña

http://www.w3.org/2001/XMLSchema#string

P2860

CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling

Rapamycin causes regression of astrocytomas in tuberous sclerosis complex

Ras, PI(3)K and mTOR signalling controls tumour cell growth

Plexiform neurofibromas.

The NF1 tumor suppressor critically regulates TSC2 and mTOR.

Requirements for therapeutic drug monitoring of sirolimus, an immunosuppressive agent used in renal transplantation.

Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus.

Body size and metabolic rate.

Malignancy in neurofibromatosis type 1.

P304

332-337

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/FTD.0B013E318286DD3F

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23666574

http://www.w3.org/2001/XMLSchema#string

P932

3660960

http://www.w3.org/2001/XMLSchema#string